Genocure Completes Technical Validation for Mass Production of Recombi…
페이지 정보
작성자Admin 조회 5 views 작성일 2025-06-10본문
Genocure Completes Technical Validation for Mass Production of Recombinant PDRN
2025-01-20
Genocure Co., Ltd., a leading company specializing in regenerative medical biomaterials, announced that it has successfully completed the technical protocol validation for the mass production of recombinant PDRN.
Genocure previously signed a CDMO-MSA agreement with Asymchem in November last year to advance the technology, establish GMP-compliant manufacturing process, and scale up production of recombinant PDRN, leveraging its proprietary next-generation production platform.
Based on this agreement, Genocure and Asymchem successfully conducted technical validation over two months.
A Genocure official stated that, the successful completion of the protocol validation for recombinant PDRN marks a key milestone in the company’s journey towards the mass production and stable supply of recombinant PDRN. The company also revealed plans to produce prototypes in the first half of the year with API (Active pharmaceutical ingredient) certification and full-scale production scheduled within the year.
If Genocure succeeds in the mass supply of recombinant PDRN, it is expected to help alleviate current supply shortage in the global regenerative medicine market – including pharmaceuticals, medical devices, and cosmetics – and significantly reshape the landscape.
Commenting on the recombinant PDRN CDMO production, CEO Oh Bo Gyeong stated, with the certification and mass production of recombinant PDRN now on track, the company is actively pursuing the expansion of its recombinant PDRN supply and related business operations. She added, as an initial step, a three-day visit starting February 22, will be hosted for a delegation from Binhai High-tech Zone in Tianjin, a national-level economic development area in China. The visit will include a business conference and corporate site tours aimed at fostering in-depth discussion on future collaboration in China.
A Genocure representative explained that Tianjin Binhai High-tech Zone, ranked as the third largest development zone in China, plays a major role in the country’s industrial growth. vel economic development area – ranked third among China’s development zones – and an industrial complex that has made significant contributions to the country’s industrial growth. The visiting delegation includes key figures such as the Director and Party Secretary of the Binhai High-tech Zone Development Committee, underscoring the importance and stature of the visit.